- Home
- LDWY vs VIVS Comparison
LDWY vs VIVS Comparison
Compare LDWY & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- VIVS
- Stock Information
- Founded
- LDWY 1990
- VIVS 2007
- Country
- LDWY United States
- VIVS United States
- Employees
- LDWY N/A
- VIVS N/A
- Industry
- LDWY Advertising
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LDWY Consumer Discretionary
- VIVS Health Care
- Exchange
- LDWY Nasdaq
- VIVS Nasdaq
- Market Cap
- LDWY 8.9M
- VIVS 8.1M
- IPO Year
- LDWY 1991
- VIVS N/A
- Fundamental
- Price
- LDWY $4.63
- VIVS $2.29
- Analyst Decision
- LDWY
- VIVS
- Analyst Count
- LDWY 0
- VIVS 0
- Target Price
- LDWY N/A
- VIVS N/A
- AVG Volume (30 Days)
- LDWY 1.4K
- VIVS 65.2K
- Earning Date
- LDWY 11-18-2025
- VIVS 11-07-2025
- Dividend Yield
- LDWY N/A
- VIVS N/A
- EPS Growth
- LDWY N/A
- VIVS N/A
- EPS
- LDWY 1.66
- VIVS N/A
- Revenue
- LDWY $71,244,000.00
- VIVS $142,000.00
- Revenue This Year
- LDWY N/A
- VIVS $42.38
- Revenue Next Year
- LDWY N/A
- VIVS $15.42
- P/E Ratio
- LDWY $3.03
- VIVS N/A
- Revenue Growth
- LDWY 187.12
- VIVS 94.52
- 52 Week Low
- LDWY $3.12
- VIVS $1.41
- 52 Week High
- LDWY $6.19
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- LDWY 38.38
- VIVS 38.36
- Support Level
- LDWY $4.69
- VIVS $2.36
- Resistance Level
- LDWY $5.04
- VIVS $2.79
- Average True Range (ATR)
- LDWY 0.22
- VIVS 0.29
- MACD
- LDWY -0.04
- VIVS -0.12
- Stochastic Oscillator
- LDWY 0.00
- VIVS 3.85
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.